challenge:

To mark empagliflozin’s approval in the EU for the treatment of adults with chronic kidney disease, Boehringer Ingelheim has held a press conference in its Regional Vienna Center with the goal to secure participation of media from the whole region, including Kazakhstan. 

approach:

In order to have Kazakhstani tier1 medical media present at the event, Action team has undertaken the following activities: ​

• Selection and invitation of 2 tier1 media for online participation​
• Arrangement of simultaneous translation during the event​
• Translation of press kit, including press text, infographics, speakers bios​
• Translation to RU and KZ languages of press conference summary​
• Provision of necessary additional information upon journalists requests​
• Fact-checking and confirming articles generated after the press conference with BI KZ team​
• Result: dedicated articles on pharmnewskz.com and pharm.reviews​